Search research articles
Contact Us
Filters
Showing results (31-40 of 341) with videos related to
Page
of 35
Sort By:
European Urology
|
August 4, 2009
Words of wisdom. Re: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo- controlled phase III trial
Stephen H Culp, Christopher G Wood
European Urology
|
February 27, 2013
Words of wisdom: re: prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials
Jose A Karam, Christopher G Wood
Future Oncology (London, England)
|
August 12, 2009
Role of cytoreductive nephrectomy in renal cell carcinoma
Edmund Chiong, Christopher G Wood, Vitaly Margulis
The Journal of Urology
|
July 24, 2012
Novel agents and approaches for advanced renal cell carcinoma
Robert Figlin, Cora Sternberg, Christopher G Wood
Current Opinion in Urology
|
August 2, 2008
Cytoreductive nephrectomy in metastatic renal cell carcinoma
Vitaly Margulis, Surena F Matin, Christopher G Wood
European Urology
|
December 3, 2014
Reporting geographic and temporal trends in renal cell carcinoma: why is this important?
Mehrad Adibi, Jose A Karam, Christopher G Wood
Urology
|
February 9, 2020
EDITORIAL COMMENT
Daniel D Shapiro, Jose A Karam, Christopher G Wood
Urologic Oncology
|
November 19, 2013
Biomarkers of renal cell carcinoma
Tin C Ngo, Christopher G Wood, Jose A Karam
World Journal of Urology
|
April 19, 2014
Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy
Dae Y Kim, Jose A Karam, Christopher G Wood
The Urologic Clinics of North America
|
November 3, 2011
The role of lymph node dissection in renal cell carcinoma
Scott E Delacroix, Brian F Chapin, Christopher G Wood
Page
of 35
Search research articles
Search
Showing results (31-40 of 341) with videos related to
Sort By:
Page
of 35
European Urology
|
August 4, 2009
Words of wisdom. Re: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo- controlled phase III trial
Stephen H Culp, Christopher G Wood
European Urology
|
February 27, 2013
Words of wisdom: re: prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials
Jose A Karam, Christopher G Wood
Future Oncology (London, England)
|
August 12, 2009
Role of cytoreductive nephrectomy in renal cell carcinoma
Edmund Chiong, Christopher G Wood, Vitaly Margulis
The Journal of Urology
|
July 24, 2012
Novel agents and approaches for advanced renal cell carcinoma
Robert Figlin, Cora Sternberg, Christopher G Wood
Current Opinion in Urology
|
August 2, 2008
Cytoreductive nephrectomy in metastatic renal cell carcinoma
Vitaly Margulis, Surena F Matin, Christopher G Wood
European Urology
|
December 3, 2014
Reporting geographic and temporal trends in renal cell carcinoma: why is this important?
Mehrad Adibi, Jose A Karam, Christopher G Wood
Urology
|
February 9, 2020
EDITORIAL COMMENT
Daniel D Shapiro, Jose A Karam, Christopher G Wood
Urologic Oncology
|
November 19, 2013
Biomarkers of renal cell carcinoma
Tin C Ngo, Christopher G Wood, Jose A Karam
World Journal of Urology
|
April 19, 2014
Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy
Dae Y Kim, Jose A Karam, Christopher G Wood
The Urologic Clinics of North America
|
November 3, 2011
The role of lymph node dissection in renal cell carcinoma
Scott E Delacroix, Brian F Chapin, Christopher G Wood
Page
of 35